The pharmaceutical industry is seeing new growth opportunities as global companies look for reliable manufacturing partners, while demand for affordable medicines and healthcare products continues to expand.
Within this space, businesses with a presence across APIs, contract manufacturing and medical devices are trying to tap multiple sources of growth. However, rising demand alone does not guarantee success, as companies must also manage competition, regulatory requirements and the cost of expansion.
Morepen Laboratories has been building its presence across pharmaceutical ingredients, contract manufacturing and medical devices. While active pharmaceutical ingredients (APIs) remain an important part of its business, the growing contribution from contract development and manufacturing organisation (CDMO) operations is changing its growth profile.
A multi-year mandate worth ₹825 crore from a global pharmaceutical company has added to this opportunity. At the same time, its glucose-monitoring products and international distribution network provide another source of revenue. The company is also working on higher-value APIs and expanding its manufacturing capabilities.
More from the author: Can This Watchmaker Challenge India’s Market Leader With 3X Revenue Growth, Global Watch Brands and Expanding Manufacturing?
This makes the business more diversified than a traditional API-focused manufacturer. However, each segment has a different growth cycle, margin profile and set of risks. Investors should therefore look at the performance of these businesses separately rather than judge the company only by its consolidated revenue growth.
Q2 FY27 results show a sharp improvement
The September quarter was a strong one for Morepen. Revenue from operations increased to ₹746.50 crore from ₹411.58 crore in Q2 FY26, a growth of around 81%. Total income stood at ₹755.19 crore, compared with ₹416.21 crore a year earlier.
The company reported a net profit of ₹88.89 crore, against ₹41.04 crore in the corresponding quarter last year. The improvement in earnings was supported by higher commercial CDMO supplies and a better business mix.
The company reported EBITDA of ₹132 crore and an EBITDA margin of 17.45%, up 897 basis points year on year. The margin improvement is worth watching because it suggests that the higher business volume is translating into better operating leverage. In simple terms, a larger share of revenue is being retained as operating earnings after meeting operating expenses.
The first half of FY27 also remained strong. Revenue from operations reached ₹1,316.63 crore, while total income was ₹1,330.50 crore. Net profit after minority interest stood at around ₹145.29 crore. The investor presentation reported H1 EBITDA of ₹220 crore and a margin of 16.50%.
These numbers indicate that the improvement is not limited to one quarter. Still, investors should watch the next few results to understand whether the higher margins can be maintained as the company continues to expand.
CDMO business is emerging as a major growth driver
The biggest development during the quarter was the scale-up of the CDMO business. Revenue from this segment increased to ₹253 crore in Q2 FY27 from ₹58 crore in Q1 FY27. This is a sharp sequential increase and shows that commercial supplies have moved to a more meaningful scale.
CDMO stands for contract development and manufacturing organisation. Such companies work with pharmaceutical customers to develop, manufacture or supply products and ingredients according to the customer’s requirements. The customer can use the manufacturer’s facilities and technical capabilities without having to build the entire manufacturing setup itself.
For a company like Morepen, this business can offer an opportunity to build longer-term relationships with global pharmaceutical players. Once a product and manufacturing process are approved, supplies can continue over an extended period, depending on the customer’s demand and the agreed programme.
CDMO revenue accounted for around 52% of the combined API and CDMO revenue in Q2 FY27. For H1 FY27, the company reported CDMO revenue of ₹311 crore. This contribution is important because it shows how quickly the business is becoming a larger part of its pharmaceutical operations.
However, CDMO is not simply about adding manufacturing capacity. Customers expect consistent quality, reliable delivery and compliance with regulatory requirements. The company will need to maintain these standards as production volumes increase.
What the ₹825 crore global mandate means
In February 2026, Morepen announced a multi-year CDMO mandate worth ₹825 crore from a global pharmaceutical company. The company subsequently started commercial supplies under this programme in July 2026. Its Q1 FY27 update referred to initial commercial dispatches of around ₹58 crore.
The mandate gives Morepen an opportunity to expand its presence in contract manufacturing and build a relationship with an international customer. It also provides a degree of visibility for future manufacturing requirements.
More from the author: Supplying Critical Aircraft Components to Airbus and Boeing, 106% H1 Profit Growth: Is This Small-cap Stock an Undiscovered Aerospace Play?
But investors should understand what the ₹825 crore figure actually represents. It is a multi-year mandate, not revenue that will be recognised immediately. The amount will be realised over the programme period, depending on the agreed supply schedule, customer demand and the company’s ability to execute orders.
Another point worth noting is that the customer has not been publicly identified. This makes it difficult for investors to assess the customer relationship independently or understand how much of the company’s CDMO business depends on this particular programme.
The real test will be whether Morepen can use this mandate as a starting point to secure additional customers and programmes. A business dependent on one or two large contracts may report strong growth, but it can also face a sudden slowdown if a customer changes its sourcing plans or reduces orders.
Export growth strengthens the international business
Exports were another major contributor to the September quarter’s performance. Export revenue increased 131% year on year to ₹397 crore in Q2 FY27. For the first half, exports reached ₹654 crore, registering growth of 122%. The company said exports accounted for approximately half of its sales revenue during H1 FY27.
Morepen has a presence in more than 90 countries and has built relationships with international pharmaceutical customers over several years. Its API business has played an important role in this presence. Around 76% of API revenue came from exports during H1 FY27.
The company is also trying to improve the product mix by focusing on newer molecules and higher-value APIs. New molecules accounted for 25% of API revenue in H1 FY27, compared with 14% in the corresponding period last year. This could support growth if the company is able to increase the contribution of specialised products.
A larger export business can reduce dependence on domestic demand and provide access to a wider customer base. However, international business also brings challenges such as regulatory requirements, currency fluctuations, pricing pressure and competition from other manufacturers.
Therefore, the sustainability of export growth will matter more than the growth percentage reported in a single quarter. Investors should track whether the company can maintain its international sales while protecting margins and ensuring timely collections.
Medical devices provide another source of growth
Morepen is not dependent only on pharmaceutical manufacturing. Its medical devices business is another important part of the overall operations.
The segment reported revenue of ₹208 crore in Q2 FY27, up 65% year on year. During H1 FY27, revenue reached ₹399 crore, registering growth of 39%.
The business is mainly associated with glucose-monitoring products, blood-pressure monitors and related consumables. The company has an installed base of around 20 million glucose meters and reports annual sales of approximately 500 million strips.
This installed base is important because the business does not end with the sale of a glucose meter. Customers who use a particular meter also need compatible test strips regularly. This creates an opportunity for repeat sales and gives the company access to an established customer base.
The medical devices business also operates through distribution and service networks. Morepen has highlighted its all-India distribution and service presence, along with backward-integrated manufacturing capabilities.
The opportunity is linked to the growing need for regular health monitoring, particularly for people managing conditions such as diabetes and high blood pressure. However, this segment also faces competition from established brands and other device manufacturers. Product quality, pricing, distribution and customer trust will remain important.
More from the author: China+1 Opportunity, Aerospace Entry and ₹1,180 Crore Order Book: Is This Lesser-Known ₹1,800 Crore Engineering Stock a Hidden Gem?
For investors, the benefit of this business is that it provides a separate growth engine alongside APIs and CDMO. The company will need to maintain growth and profitability in this segment as well.
Capacity expansion towards 800 KL
To support the growing pharmaceutical business, Morepen has expanded its combined API and CDMO manufacturing capacity to 614 KL. The company said the first phase of expansion was completed ahead of schedule. Civil work has also started for the next phase, which is expected to take capacity towards 800 KL by Q2 FY28.
The expansion is linked to the company’s ambition to handle larger global manufacturing programmes. It is also working on high-potency APIs, new technologies and an innovation hub to strengthen its technical capabilities.
This is important because global pharmaceutical customers generally look for manufacturers that can offer more than basic production capacity. They need reliable processes, quality systems, regulatory compliance and the ability to scale up manufacturing when demand increases.
However, capacity expansion also involves financial commitments. New facilities require investment in equipment, infrastructure, employees and compliance systems. If orders do not grow at the same pace as capacity, utilisation may remain low and the additional fixed costs could affect profitability.
Therefore, the next phase of expansion should be judged not only by the capacity added but also by the orders secured and the utilisation achieved.
First US ANDA submission adds to its product pipeline
Another development worth tracking is Morepen’s first US Abbreviated New Drug Application (ANDA) submission for Sitagliptin tablets in 25 mg, 50 mg and 100 mg strengths. The company announced this development in September 2026.
An ANDA is a regulatory application submitted to the US Food and Drug Administration for approval to market a generic version of an already approved medicine. It requires the applicant to demonstrate that the generic product meets the required standards, including equivalence to the reference drug.
This submission is relevant because it indicates a move towards finished-dose development in addition to the company’s API and CDMO activities. It could allow Morepen to participate in another part of the pharmaceutical value chain.
However, investors should not treat the submission as an approved product or an immediate revenue opportunity. Regulatory approval, commercial launch and the ability to compete in the US market are separate steps. The financial contribution will become clearer only when the company provides further updates.
What lies ahead?
Morepen Laboratories has delivered a strong first half of FY27, with growth coming from CDMO, exports and medical devices. The ₹825 crore mandate, expansion towards 800 KL and its first US ANDA submission provide additional opportunities for the business.
Stock target: Mid Cap Stock to Buy Now for an Upside of 21%; Recommended by Trade Brains Portal
However, the next phase will be about execution rather than announcements. The company needs to convert its CDMO pipeline into regular commercial supplies, add more global customers and ensure that new manufacturing capacity is utilised efficiently. It also needs to maintain quality standards and improve cash generation as the business grows.
For investors, the company is worth tracking because its business mix is changing and the latest results show a meaningful improvement in earnings. But the growth story still needs to prove its consistency. The next few quarters should provide a clearer picture of whether the CDMO ramp-up can continue, whether margins remain healthy and whether reported profits translate into cash.
